Monocyte chemotactic protein-1 (MCP-1) /CCL2 is a member of the CC chemokine family and plays an important role in cardiovascular disease. Increased MCP-1 expression levels were detected under a variety of pathological conditions, associated with inflammation and mononuclear cell infiltration. MCP-1 expression level can also be used as a prognostic biomarker for acute coronary syndrome (ACS), and the MCP-1 axis is also a therapeutic target for ACS. Creative BioMart Biomarker is capable to provide our customers with superior MCP-1 detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Introduction
The human chemokine family can be divided into four subfamilies based on the number of amino acids in the first two of the four conserved cysteine residues, including CC, CXC, C, or CX3C. MCP-1 is the most studied CC chemokine. It was initially identified as a monocyte-specific chemokine, and later proved to attract T lymphocytes and NK cells, but not neutrophils. MCP-1 binds to the seven transmembrane G-protein coupled receptor CCR2, and the resulting signal recruit monocytes to the inflammation site.
Figure 1. MCP-1-induced signalling events in cardiovascular disease.
Many major diseases, including cardiovascular disease, are considered inflammatory diseases, and MCP-1 plays a vital role in the development of cardiovascular disease. MCP-1 is involved in the formation, development, and instability of atherosclerotic plaques, and plays an important role in remodeling after infarction. Increased MCP-1 expression levels were detected in a variety of pathological conditions, associated with inflammation and mononuclear cell infiltration. A large number of experiments have demonstrated that MCP-1 is highly expressed in atherosclerotic plaques and mediates the recruitment of macrophages in atherosclerotic lesions. The interaction of MCP-1 with CCR2 triggered an integrin-mediated adhesion interaction between monocytes and endothelial cells, which eventually led to leukocyte diapedesis into the subendothelium. After entering the subendothelial space, monocytes differentiate into macrophages, continuously take up lipids, and eventually become foam cells, triggering the formation of fatty streaks, which leads to the formation of atherosclerotic plaques. In addition, MCP-1 plays a major role in myocarditis, ischemia/reperfusion injury, and in transplant reiection, and is also involved in ischemic angiogenesis. Studies have shown that after ACS, plasma levels of MCP-1 have prognostic value in the acute or chronic phase. High plasma levels of MCP-1 may reflect a higher burden of atherosclerotic disease and may play a role in thrombosis, leading to recurrent coronary events.
Figure 2. The role of MCP-1 in atherothrombotic disease.
Application of MCP-1
Plasma levels of MCP-1, can be used as a potential biomarker for cardiovascular disease.
Our Advantages
- Accept a wide range of sample types
- Provide multiple detection methods
- Ensure high sensitivity for detecting MCP-1 in different samples
- Ensure high accuracy and repeatable MCP-1 detection
- Ensure a wide kinetic range to detect samples of different concentrations
- Short experimental period
Workflow of MCP-1 Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the MCP-1 detection procedure to ensure high sensitivity, high accuracy and repeatable MCP-1 detection.
Please feel free to contact us if you would like to know more about MCP-1 detection. At Creative BioMart Biomarker, we not only provide high-quality MCP-1 detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
References:
- Gonzalez-Quesada, C.; Frangogiannis, N.G. Monocyte chemoattractant protein (MCP-1)/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep. 2009, 11(2): 131–138.
- Niu, J.; Kolattukudy, P.E. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond). 2009, 117(3): 95-109.
